FierceBiotech Apr 20, 2026 FDA celebrates progress to end animal testing but experts warn there’s still a long way to go
FierceBiotech Apr 20, 2026 AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
FierceBiotech Apr 18, 2026 AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
FierceBiotech Apr 17, 2026 UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine
FierceBiotech Apr 17, 2026 Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans
FierceBiotech Apr 17, 2026 A new benchmark for biotech IPOs? Kailera raises $625M to fund obesity pipeline
FierceBiotech Apr 17, 2026 Small pools, big ideas: How the rare disease community is reimagining clinical trials
FierceBiotech Apr 16, 2026 RyghtAI launches clinical site search engine to aid drug developers, CROs with trial design
FierceBiotech Apr 16, 2026 Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal
FierceBiotech Apr 16, 2026 Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
FierceBiotech Apr 16, 2026 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again